Food Tech Talk

The episode contains a handful of genuinely useful non-obvious insights - the global de-harmonisation of GRAS acceptance, the 'FDA silence ≠ permission' principle, and the infant formula case study - but they are heavily diluted by repeated platitudes ('bring them in early,' 'planning makes a difference') and generic cross-functional collaboration advice that adds little per minute.

“just because FDA doesn't say you can't do it doesn't mean you can”

“Each country has a different where it used to be, you know, if it was FEMA grass or FDA grass, most countries accepted that. So less and less we're becoming more unharmonized”

The analogy of regulatory gaining a board seat following the same trajectory as food safety post-outbreak is a clean, fresh frame, and the counterintuitive point about FDA silence not constituting permission is genuinely useful; however, the bulk of the episode recycles standard 'integrate regulatory early' and 'seat at the table' talking points that circulate constantly in food-industry circles.

“do you remember when food safety was it was always a thing, but it wasn't part of a leadership team until there were all these high profile outbreaks”

“one of the biggest losing ways to go in to advocate for yourself is to go in and say, this is going to cost us a lot of money”

Susan Bond is a genuine practitioner with real FDA policy work (BSE crisis, mercury-fish joint press conference with EPA) and documented industry results (infant formula interim final rule campaign), placing her firmly above the 'career thought leader' tier; she is now a boutique consultant rather than an active operator at scale, which limits the score.

“I literally flew in. I called them drive bys, but I went to FDA, I interacted with them seven times in 45 days”

“we were able to persuade FDA about 12 points of this rule. We were able to make an impact on 10 of them”

The infant formula case is the episode's strongest moment, with concrete numbers (45 days, 7 FDA interactions, 4 US manufacturers, ~$2M annual testing, 10 of 12 rule points changed) that a B2B operator can actually learn from; the rest of the episode is largely abstract, with no company names, no market-size data, and vague references to 'a couple CPGs.'

“capital investments, like 10 millions annual testing investments of 2 million”

“there's only really about four companies in the United States that make infant formula”

The host asks reasonably structured open-ended questions and does follow the thread from regulatory as checkbox to regulatory as competitive advantage, but there is zero pushback on vague claims, no probing on specific failures or costs, and the interview ends with unalloyed praise - making it a courteous but largely unchallenging conversation.

“Was there a defining moment at, you know, either the FDA or in one of your roles after the government that started to shape how you look at the role of regulation in innovation”

“Great points Susan. Thank you so much for the insights, the stories and just, you know, sharing your expertise with us on the podcast”